FDA Inspection 1059781 — Theravance Biopharma US, Inc.
The FDA completed an inspection of Theravance Biopharma US, Inc. on Jul 12, 2018 in South San Francisco, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 12, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- South San Francisco, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)